Sartorius Stedim Biotech
€208.20Change from previous close: +0.97%Absolute change: +€2.00
At a glance
- Revenue growth
- +6.74%
- 2025 vs 2024
- Net income growth
- +51.68%
- 2025 vs 2024
- Net margin
- 9.0%
- 2024: 6.3%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 2,968 | 2,780 | 2,776 | 3,493 | — |
| Cost of revenue | 1,622 | 1,573 | 1,542 | 1,675 | — |
| Gross profit | 1,345 | 1,207 | 1,234 | 1,817 | — |
| Selling, general and administrative | 661 | 649 | 616 | 612 | — |
| Research and development | 133 | 144 | 130 | 132 | — |
| Operating income | 539 | 398 | 471 | 1,055 | — |
| EBIT | 513 | 369 | 519 | 1,149 | — |
| EBITDA | 831 | 671 | 756 | 1,331 | — |
| Interest expense | 140 | 150 | 117 | 18.6 | — |
| Pre-tax income | 373 | 219 | 402 | 1,130 | — |
| Income tax | 107 | 40.7 | 89.2 | 251 | — |
| Net income | 266 | 175 | 310 | 876 | — |
| Net income to common shareholders | — | 175 | 310 | 876 | 414 |
| Basic EPS | 2.73 | 1.81 | 3.37 | 9.51 | — |
| Diluted EPS | 2.73 | 1.81 | 3.37 | 9.51 | — |
| Average shares (basic) | 97.3 | 96.7 | 92.2 | 92.2 | — |
| Average shares (diluted) | 97.3 | 96.7 | 92.2 | 92.2 | — |